EVAXION BIOTECH A/S ADS news, videos and press releases
For more news please use our advanced search feature.
EVAXION BIOTECH A/S ADS - More news...
EVAXION BIOTECH A/S ADS - More news...
- Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01
- Evaxion announces completion of ADS ratio change
- Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
- Evaxion announces plan to implement ADS ratio change
- Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity
- Evaxion establishes new AI-derived precision cancer vaccine concept
- Evaxion announces 2025 milestones reflecting continued strong strategy execution
- Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress
- Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
- Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
- Evaxion announces business update and third quarter 2024 financial results
- Evaxion to announce business update and third quarter 2024 financial results on October 31
- Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
- Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
- Evaxion significantly expands vaccine development collaboration with MSD
- Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
- Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
- Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
- Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results
- Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
- Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
- Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
- Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
- Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
- Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
- Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
- Evaxion Announces Business Update and First Quarter 2024 Financial Results
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
- Evaxion Receives Nasdaq Notification
